Current and Future Perspectives in the Treatment of High-risk MDS

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: May 31, 2021
Expiration Date: May 31, 2022

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Join Dr. Richard Stone as he explores current and future treatments for high-risk myelodysplastic syndromes (MDS). Topics will include risk assessment and stratification systems, venetoclax as monotherapy or in combination with hypomethylating agents, the implications of TP53 mutations, and the role of investigational agents in high-risk MDS, including oral cedazuridine/decitabine, enasidenib, pevonedistat, APR-246, magrolimab, and sabatolimab.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Consider current approaches to the treatment of patients with high-risk MDS
  • Identify therapies and treatment combinations that are being explored in clinical trials for the treatment of patients with high-risk MDS
  • Outline special populations in high-risk MDS and the clinical implication of TP53-mutated MDS
  • Evaluate emerging data from clinical trials on treatment regimens for special populations in high-risk MDS


Current and Future Perspectives in the Treatment of High-risk MDS – Richard Stone, MD

Instructions for Participation and Credit

This activity is eligible for credit through May 31, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Richard Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director of Translational Research, Leukemia Division
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Richard Stone received his medical degree from Harvard Medical School, Boston. He completed his internal medicine residency training at Brigham and Women’s Hospital and his hematology-oncology fellowship at Dana-Farber Cancer Institute (DFCI). He is Chief of Staff and Director of Translational Research for the Leukemia Division in the Department of Medical Oncology at DFCI, and Professor of Medicine at Harvard Medical School. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies, including acute leukemia (AML), myeloproliferative disorders, and myelodysplastic syndrome (MDS) ‒ a bone marrow failure state that may convert to leukemia.

In addition to his work at DFCI, Dr. Stone serves as Chairman of the Leukemia Committee for the national cooperative trials group, Alliance. He is a vice chair of the National Comprehensive Cancer Network (NCCN) MDS panel and is also a member of the NCCN AML panel. Dr. Stone has participated extensively in teaching courses on leukemia and related disorders. He is the author of many academic papers that have been published in the New England Journal of Medicine, Blood, Leukemia, and numerous other journals. He had a significant leadership role in the development of five new drugs for the treatment of AML that were approved in the past two years, and is the co-principal investigator of the SPORE in Myeloid Malignancies at Dana-Farber/Harvard Cancer Center.


MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-024-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Richard Stone has received honoraria related to formal advisory activities from AbbVie Inc., Actinium Pharmaceuticals, Inc., Aprea Therapeutics, BerGenBio ASA, ElevateBio, Foghorn Therapeutics, GEMoaB GmbH, GlaxoSmithKline plc, Innate Pharma, Inc., Onconova Therapeutics, Syndax, and Syros Pharmaceuticals, Inc., as well as steering committee activities from AbbVie.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Scott J. Hershman, MD, FACEHP, CHCP, Educational Program Director, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc.

©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.